M. Blommers is the CSO of Saverna Therapeutics. His biotech company targets non-coding RNA using a unique platform of NMR, machine learning and cell biology. The team has more than a decade of experience managing multidisciplinary drug research projects in pharmaceutical companies. The cheminformatics tools and expertise will be used to advance Covid19-NMR.

Blommers has written 90 publications and patents, the h-index is 35.